At a glance
ClinicalIndex Comparison RecordPhase 2Active· 124 enrolled
Drug / intervention
ACP-196 (acalabrutinib)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating ACP-196 (acalabrutinib) for Mantle Cell Lymphoma (MCL). Active but no longer recruiting, targeting 124 participants across 58 sites in 10 countries.
Detailed Summary
The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle Cell Lymphoma (MCL)
CountriesAustralia, Belgium, Czechia, France, Italy, Netherlands, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2Active
2015201620172018201920202021202220232024202520262027
First PostedAug 2014
Enrollment StartMar 2015
Primary CompletionDec 2020
TodayJul 2026
Study CompletionSep 2026
First PostedAug 12, 2014
Enrollment StartMar 2, 2015
Primary CompletionDec 4, 2020
Study CompletionSep 6, 2026
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 11.9 years ago
Interventions
ACP-196 (acalabrutinib)drug